Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 9Phase 3 8Phase NA 5Phase 1/2 5Phase 2/3 3Phase 4 2

Status

Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Pancreatic Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 5Neoplasms 5Sarcoma 3Precision Cell Immunotherapy 3Ovarian Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Glioblastoma 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Mesothelioma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Ovarian Epithelial 2Virus Diseases 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Drug Therapy × Clear all
NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

LARKSPUR BIOSCIENCES, INC.

Phase 1/2 Not yet recruiting
120 enrolled
Tumor-Agnostic

Neoplasms

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT06228326 2025-10-24

KYANITE-1

Krystal Biotech, Inc.

Phase 1/2 Recruiting
250 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Capital Medical University

Phase 1/2 Completed
40 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡